" class="no-js "lang="en-US"> Abbott Announces European Launch of Amplatzer™ Talisman™ System to Close Hole in Heart for People at Risk of Recurrent Stroke - Medtech Alert
Tuesday, December 05, 2023

Abbott Announces European Launch of Amplatzer™ Talisman™ System to Close Hole in Heart for People at Risk of Recurrent Stroke

Abbott today announced the European launch of its Amplatzer™ Talisman™ PFO Occlusion System to treat people with a patent foramen ovale (PFO) – a hole in the heart that doesn’t close following birth – who have experienced a stroke and are at risk of having another. The new Talisman PFO occluders come pre-attached to the delivery cable, designed to reduce preparation time for doctors and making the system easier to use.

Nearly one in four people have a PFO[i], which may allow blood clots to pass from the right side of the heart to the left, from where they can eventually travel to the brain. For patients who have suffered a stroke, physicians may opt for occlusion (or closure) of the PFO through a minimally invasive, catheter-based procedure using a device like the Talisman system to seal off the opening to reduce the risk of another stroke.

“Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke,” said Matthew Daniels, BSc, MA, MB BChir, MRCP, FSCAI, honorary consultant cardiologist in Manchester, England, who completed the first European procedure with the Talisman system. “We’re excited that physicians around Europe now have access to the Talisman device to help reduce patients’ risk and worry of experiencing another stroke.”

The Amplatzer Talisman system builds off the company’s industry-leading Amplatzer PFO Occluder. While physicians had to attach the Amplatzer PFO Occluder to the delivery cable before performing the implant procedure, the Talisman occluder now comes pre-assembled to the Amplatzer Trevisio™ delivery cable, reducing prep time ahead of the procedure and making it easier to use. The Talisman system accommodates a wide range of patient anatomies and an updated 30mm occluder size optimizes how it fits in the heart. The Talisman device is fully recapturable and repositionable so doctors can easily make adjustments for accurate placement.

“Our trusted PFO closure technology has been used to treat more than 180,000 people worldwide and we haven’t let up on continuing to innovate to best serve physicians and patients,” said Michael Dale, senior vice president of Abbott’s structural heart business. “The Talisman system simplifies the procedure for doctors and helps patients quickly get back to living fuller, healthier lives.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more